Compare Agilent Technologies Inc (A) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Marqeta Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Marqeta Inc trades at $15.52 (market cap $1.62B). The key difference: Agilent Technologies Inc is far larger — about 25.9× Marqeta Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| A | MQ | |
|---|---|---|
Market Cap | $42.00B | $1.62B |
Sector | Health | Technology |
52-Week High | $157.20 | $26.00 |
52-Week Low | $110.24 | $15.04 |
Enterprise Value | $43.55B | $939.53M |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Marqeta (MQ) trades at $15.96, down 4.37% on the day, with a bearish technical signal. The company reported Q2 2026 earnings with a beat on EPS and 17% net revenue growth, marking its second consecutive quarter of GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion. However, valuation ratios remain elevated with a P/E of 177.28, and net income margin is thin at 1.53%.
The outlook is mixed; analyst consensus is a Buy with a $19.00 price target, implying upside, but execution on growth initiatives like stablecoin cards and European expansion is key. Risks include high valuation sensitivity and competitive pressures in fintech. Positive cash flow trends and recent profitability improvements provide a foundation for cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
